From Name:
From Email:
To Name:
To Email:

Optional Message:


Apixaban approved for clot-risk reduction in nonvalvular atrial fibrillation

from American Society of Health-System Pharmacists

The FDA on Dec. 28 approved apixaban oral tablets to reduce the risk of stroke and systemic embolism in patients with nonvavular atrial fibrillation. The factor Xa inhibitor will be marketed as Eliquis by Bristol-Myers Squibb. The company expects the product to be widely available by the end of January. more


Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063